Aim: To elucidate whether warming may reduce the viscosity of miriplatin-lipiodol suspension (MPT/LPD) and also the injection pressure through microcatheters, for potential use as a chemotherapeutic agent of transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).

Methods: Viscosity of MPT/LPD prepared at on-label dose was measured in vitro at 25°C, 30°C, 40°C, 50°C and 60°C using capillary tube method. Reproducibility of viscosity change was also tested. Injection pressure through two different commercially available microcatheters was measured using a rheometer. Data sampling was performed at least twice for each measurement.

Results: Viscosity of MPT/LPD was significantly reduced as the temperature was elevated (R(2)  = 0.9586, P < 0.0001, Pearson's correlation); at 40°C, it was almost half of that at room temperature (25°C). Repeated warming and cooling down of MPT/LPD revealed good reproducibility of viscosity change. Injection pressure through either microcatheter showed significant reduction when MPT/LPD was warmed (P < 0.05, Spearman's rank correlation coefficient).

Conclusion: The viscosity and injection pressure through microcatheters of MPT/LPD was confirmed to reduce significantly as the temperature is elevated. MPT/LPD warmed to 40°C has half viscosity as that at room temperature and is considered suitable for clinical use. Warming MPT/LPD may have potential to facilitate the procedure of TACE for HCC.

Download full-text PDF

Source
http://dx.doi.org/10.1111/hepr.12050DOI Listing

Publication Analysis

Top Keywords

miriplatin-lipiodol suspension
8
potential chemotherapeutic
8
chemotherapeutic agent
8
agent transarterial
8
transarterial chemoembolization
8
hepatocellular carcinoma
8
injection pressure
8
viscosity mpt/lpd
8
warming miriplatin-lipiodol
4
suspension potential
4

Similar Publications

Transcatheter arterial chemoembolization (TACE) is a standard treatment for unresectable hepatocellular carcinoma; however, it does not always result in tumor control. Nevertheless, treatment outcome can be improved with monodisperse emulsions of anticancer agents. In this study, the distribution of a monodisperse miriplatin-Lipiodol emulsion in the tumor and its safety were evaluated in ten Japanese white rabbits.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the safety and feasibility of repeating transarterial chemoembolization (TACE) using a miriplatin-lipiodol suspension for treating patients with hepatocellular carcinoma (HCC).
  • Sixteen patients were analyzed, with the study measuring the total doses of miriplatin, lipiodol, and other materials used, along with any adverse events during their first and last TACE sessions.
  • Results showed an average of 3.7 TACE sessions per patient without significant differences in adverse effects between the first and last procedures, concluding that repeated TACE with this method is both safe and feasible for selected patients.
View Article and Find Full Text PDF

Aim: The effect of transcatheter arterial chemoembolization (TACE) is not necessarily sufficient in patients with multiple hepatocellular carcinoma (HCC). We evaluated the antitumor activity and adverse events of TACE using warmed miriplatin suspension for multiple HCC.

Methods: Seventy patients with multiple HCC received TACE using warmed miriplatin/lipiodol suspension, including patients who were TACE-naïve (group A, n = 5), those undergoing initial TACE after radical therapies (group B, n = 31), and those with a history of repeated TACE (group C, n = 34).

View Article and Find Full Text PDF

Preparation, Characterization, and Antitumor Activities of Miriplatin-Loaded Liposomes.

J Pharm Sci

January 2016

Pharmaceutics Department, Institute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100050, PR China. Electronic address:

Because of the insolubility of miriplatin in water, miriplatin and lipiodol suspension is the sole formulation of miriplatin approved in Japan to treat hepatocellular carcinoma by transcatheter arterial chemoembolization. Until now, there have been no reports of other pharmaceutical formulations of miriplatin except miriplatin/lipiodol suspension. In this study, we aimed not only to develop miriplatin-loaded liposomes (lipomiriplatins) which could be administrated systematically for tumors besides hepatocellular carcinoma but also to ascertain whether miriplatin, like its analog of NDDP, was a liposome-dependent antitumor agent.

View Article and Find Full Text PDF

The effects of warming or emulsification with the water-soluble contrast medium, Iomeron (IOM), on reducing the viscosity of miriplatin-lipiodol (MPT-LPD) suspension were studied. Reduction in the viscosity of MPT-LPD suspension was ob- served upon increasing the temperature. Although the O/W MPT-LPD emulsion with a low ratio of MPT-LPD to IOM reduced the viscosity, the effect was lesser than that achieved with the warming treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!